Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.0195994887089902 -0.0200255645504901 -0.0195994887089902
Stock impact report

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies [Reuters]

Actelis Networks, Inc. (ASNS) 
Last actelis networks, inc. earnings: 11/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.arsanis.com/investor-relations
Company Research Source: Reuters
BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies | Reuters Reuters Staff 1 Min Read April 4 (Reuters) - Arsanis Inc: * BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com) All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. Show less Read more
Impact Snapshot
Event Time:
ASNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ASNS alerts
Opt-in for
ASNS alerts

from News Quantified
Opt-in for
ASNS alerts

from News Quantified